Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy, Intensity-Modulated | 9 | 2023 | 801 | 2.100 |
Why?
|
Oropharyngeal Neoplasms | 8 | 2023 | 491 | 1.640 |
Why?
|
Head and Neck Neoplasms | 13 | 2023 | 2876 | 1.420 |
Why?
|
Nasopharyngeal Neoplasms | 4 | 2021 | 286 | 1.260 |
Why?
|
Radiation Oncology | 3 | 2023 | 560 | 1.200 |
Why?
|
Paranasal Sinus Neoplasms | 8 | 2016 | 240 | 1.070 |
Why?
|
Carcinoma, Adenoid Cystic | 4 | 2016 | 259 | 0.990 |
Why?
|
Skull Base | 2 | 2016 | 291 | 0.800 |
Why?
|
Relative Biological Effectiveness | 2 | 2021 | 312 | 0.780 |
Why?
|
Carcinoma, Squamous Cell | 10 | 2023 | 4025 | 0.740 |
Why?
|
Radiotherapy Dosage | 13 | 2023 | 2895 | 0.730 |
Why?
|
Diagnostic Techniques, Ophthalmological | 3 | 2006 | 250 | 0.640 |
Why?
|
Lymphoma, Extranodal NK-T-Cell | 1 | 2019 | 45 | 0.630 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2021 | 1659 | 0.630 |
Why?
|
Skull Base Neoplasms | 3 | 2012 | 269 | 0.600 |
Why?
|
Visual Perception | 3 | 2015 | 1371 | 0.590 |
Why?
|
Nose Neoplasms | 3 | 2016 | 249 | 0.560 |
Why?
|
Radiotherapy | 4 | 2018 | 1503 | 0.550 |
Why?
|
Monte Carlo Method | 1 | 2021 | 1252 | 0.510 |
Why?
|
Papillomavirus Infections | 6 | 2023 | 1598 | 0.470 |
Why?
|
Macula Lutea | 2 | 2006 | 168 | 0.460 |
Why?
|
Carcinoma | 5 | 2021 | 2334 | 0.440 |
Why?
|
Temporal Lobe | 1 | 2021 | 1687 | 0.430 |
Why?
|
Osteoradionecrosis | 1 | 2012 | 51 | 0.420 |
Why?
|
Touch | 1 | 2015 | 312 | 0.410 |
Why?
|
Tomography, Optical Coherence | 4 | 2006 | 2873 | 0.410 |
Why?
|
Sphenoid Sinus | 2 | 2009 | 99 | 0.390 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2012 | 136 | 0.390 |
Why?
|
Cutaneous Fistula | 1 | 2012 | 79 | 0.390 |
Why?
|
Neoplasm Metastasis | 5 | 2019 | 4883 | 0.390 |
Why?
|
Paranasal Sinus Diseases | 1 | 2012 | 121 | 0.370 |
Why?
|
Somatosensory Cortex | 1 | 2015 | 510 | 0.370 |
Why?
|
Fistula | 1 | 2012 | 215 | 0.350 |
Why?
|
Parietal Lobe | 1 | 2015 | 850 | 0.340 |
Why?
|
Deglutition Disorders | 2 | 2013 | 629 | 0.330 |
Why?
|
Cerebellar Neoplasms | 1 | 2012 | 585 | 0.290 |
Why?
|
Retina | 3 | 2013 | 2634 | 0.290 |
Why?
|
Medulloblastoma | 1 | 2012 | 677 | 0.290 |
Why?
|
Enteral Nutrition | 1 | 2013 | 782 | 0.280 |
Why?
|
Disease-Free Survival | 8 | 2017 | 6813 | 0.280 |
Why?
|
Papillomaviridae | 6 | 2022 | 1116 | 0.270 |
Why?
|
Canthaxanthin | 1 | 2006 | 3 | 0.270 |
Why?
|
Pyrroles | 1 | 2012 | 1135 | 0.260 |
Why?
|
Human Body | 1 | 2004 | 37 | 0.240 |
Why?
|
Angiogenesis Inhibitors | 2 | 2012 | 2048 | 0.240 |
Why?
|
Extremities | 1 | 2010 | 864 | 0.240 |
Why?
|
Neuroma, Acoustic | 2 | 2005 | 455 | 0.230 |
Why?
|
Face | 1 | 2010 | 1015 | 0.230 |
Why?
|
Indoles | 1 | 2012 | 1828 | 0.230 |
Why?
|
Photic Stimulation | 1 | 2010 | 1967 | 0.220 |
Why?
|
Middle Aged | 32 | 2023 | 219653 | 0.220 |
Why?
|
Retinal Perforations | 1 | 2004 | 137 | 0.220 |
Why?
|
Visual Fields | 1 | 2010 | 1053 | 0.210 |
Why?
|
Stereotaxic Techniques | 1 | 2005 | 548 | 0.210 |
Why?
|
Urea | 1 | 2004 | 443 | 0.200 |
Why?
|
Visual Cortex | 1 | 2010 | 1089 | 0.200 |
Why?
|
Organs at Risk | 2 | 2021 | 358 | 0.190 |
Why?
|
Aged | 25 | 2023 | 168617 | 0.190 |
Why?
|
Nasolacrimal Duct | 1 | 2022 | 76 | 0.190 |
Why?
|
Brain Mapping | 2 | 2015 | 6559 | 0.190 |
Why?
|
Macular Edema | 1 | 2005 | 375 | 0.190 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2022 | 102 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2018 | 9269 | 0.180 |
Why?
|
Adult | 25 | 2021 | 219390 | 0.180 |
Why?
|
Neurofibromin 2 | 3 | 2012 | 270 | 0.180 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39216 | 0.180 |
Why?
|
Gastrostomy | 2 | 2013 | 322 | 0.180 |
Why?
|
Male | 32 | 2023 | 358719 | 0.170 |
Why?
|
Radiation Injuries | 2 | 2018 | 1183 | 0.170 |
Why?
|
Retinal Diseases | 1 | 2006 | 702 | 0.170 |
Why?
|
Humans | 48 | 2023 | 759255 | 0.170 |
Why?
|
Antineoplastic Agents | 2 | 2012 | 13621 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2013 | 3519 | 0.170 |
Why?
|
Female | 31 | 2023 | 390240 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 218 | 0.160 |
Why?
|
Smoking | 2 | 2016 | 9066 | 0.160 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2329 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6532 | 0.160 |
Why?
|
Radiation Tolerance | 1 | 2021 | 480 | 0.160 |
Why?
|
Radiosurgery | 2 | 2005 | 1341 | 0.160 |
Why?
|
Treatment Outcome | 11 | 2021 | 64879 | 0.150 |
Why?
|
Paranasal Sinuses | 2 | 2012 | 264 | 0.150 |
Why?
|
Antioxidants | 1 | 2006 | 1668 | 0.150 |
Why?
|
Prognosis | 9 | 2023 | 29561 | 0.150 |
Why?
|
Nasal Cavity | 3 | 2012 | 304 | 0.150 |
Why?
|
Tracheotomy | 1 | 2018 | 167 | 0.140 |
Why?
|
Retrospective Studies | 17 | 2023 | 80121 | 0.140 |
Why?
|
Karnofsky Performance Status | 1 | 2016 | 165 | 0.130 |
Why?
|
Survival Rate | 5 | 2016 | 12800 | 0.130 |
Why?
|
Neurilemmoma | 2 | 2012 | 523 | 0.130 |
Why?
|
Lymphatic Irradiation | 1 | 2016 | 115 | 0.130 |
Why?
|
Aged, 80 and over | 10 | 2017 | 58867 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 580 | 0.120 |
Why?
|
Tumor Burden | 1 | 2021 | 1886 | 0.120 |
Why?
|
Neoplasm Staging | 6 | 2023 | 11123 | 0.120 |
Why?
|
Young Adult | 7 | 2021 | 58483 | 0.120 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 573 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 391 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2023 | 2007 | 0.120 |
Why?
|
Laryngeal Neoplasms | 1 | 2018 | 514 | 0.120 |
Why?
|
Maxillary Sinus Neoplasms | 1 | 2014 | 39 | 0.110 |
Why?
|
Uncertainty | 1 | 2019 | 754 | 0.110 |
Why?
|
Protons | 3 | 2009 | 1113 | 0.110 |
Why?
|
Neoplasms | 2 | 2021 | 22019 | 0.110 |
Why?
|
Physical Stimulation | 1 | 2015 | 518 | 0.110 |
Why?
|
Radiometry | 1 | 2018 | 813 | 0.110 |
Why?
|
Xerostomia | 1 | 2013 | 94 | 0.110 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12522 | 0.110 |
Why?
|
Neuroectodermal Tumors | 1 | 2012 | 22 | 0.100 |
Why?
|
Genes, Neoplasm | 1 | 2014 | 370 | 0.100 |
Why?
|
Fingers | 1 | 2015 | 505 | 0.100 |
Why?
|
Ischemic Attack, Transient | 1 | 2017 | 899 | 0.100 |
Why?
|
Esophageal Stenosis | 1 | 2013 | 194 | 0.100 |
Why?
|
Vision, Ocular | 1 | 2015 | 453 | 0.100 |
Why?
|
Neck Dissection | 1 | 2013 | 200 | 0.100 |
Why?
|
Postoperative Complications | 2 | 2012 | 15672 | 0.090 |
Why?
|
Nutritional Support | 1 | 2013 | 172 | 0.090 |
Why?
|
Narcotics | 1 | 2013 | 336 | 0.090 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2012 | 242 | 0.090 |
Why?
|
Etoposide | 1 | 2012 | 628 | 0.090 |
Why?
|
Cranial Fossa, Anterior | 1 | 2009 | 13 | 0.090 |
Why?
|
Deglutition | 1 | 2011 | 208 | 0.090 |
Why?
|
Analysis of Variance | 2 | 2012 | 6242 | 0.090 |
Why?
|
Oropharynx | 1 | 2009 | 131 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 6 | 2021 | 36160 | 0.080 |
Why?
|
Wnt Proteins | 1 | 2013 | 718 | 0.080 |
Why?
|
Constriction, Pathologic | 1 | 2011 | 1101 | 0.070 |
Why?
|
Eye Neoplasms | 1 | 2010 | 306 | 0.070 |
Why?
|
Lacrimal Apparatus | 1 | 2010 | 220 | 0.070 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2007 | 74 | 0.070 |
Why?
|
Models, Statistical | 2 | 2019 | 5066 | 0.070 |
Why?
|
Neuroglia | 1 | 2013 | 944 | 0.070 |
Why?
|
Neutrons | 1 | 2006 | 77 | 0.070 |
Why?
|
Gene Expression | 1 | 2019 | 7593 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2012 | 1788 | 0.070 |
Why?
|
Cranial Fossa, Posterior | 1 | 2006 | 135 | 0.070 |
Why?
|
Cisplatin | 1 | 2012 | 1642 | 0.060 |
Why?
|
Cavernous Sinus | 1 | 2006 | 122 | 0.060 |
Why?
|
Neoplasm Invasiveness | 2 | 2014 | 3619 | 0.060 |
Why?
|
Survival Analysis | 3 | 2014 | 10185 | 0.060 |
Why?
|
Body Weights and Measures | 1 | 2006 | 208 | 0.060 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2009 | 346 | 0.060 |
Why?
|
Time Factors | 4 | 2017 | 40109 | 0.060 |
Why?
|
Triamcinolone Acetonide | 1 | 2005 | 100 | 0.060 |
Why?
|
Peroxides | 1 | 2004 | 73 | 0.060 |
Why?
|
Risk Factors | 5 | 2017 | 74167 | 0.060 |
Why?
|
Adolescent | 5 | 2018 | 87560 | 0.060 |
Why?
|
Neovascularization, Pathologic | 2 | 2012 | 2635 | 0.060 |
Why?
|
Pattern Recognition, Visual | 1 | 2010 | 810 | 0.060 |
Why?
|
Regression Analysis | 1 | 2013 | 6359 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2015 | 8929 | 0.060 |
Why?
|
Forecasting | 1 | 2013 | 2931 | 0.060 |
Why?
|
Quinazolines | 1 | 2010 | 1362 | 0.060 |
Why?
|
Reaction Time | 1 | 2010 | 2075 | 0.050 |
Why?
|
Oxygen | 1 | 2015 | 4188 | 0.050 |
Why?
|
Sarcoma | 2 | 2012 | 1786 | 0.050 |
Why?
|
Cranial Nerves | 1 | 2003 | 98 | 0.050 |
Why?
|
Residence Characteristics | 1 | 2013 | 2035 | 0.050 |
Why?
|
Carbon | 1 | 2006 | 671 | 0.050 |
Why?
|
Combined Modality Therapy | 5 | 2018 | 8549 | 0.050 |
Why?
|
Cytoskeleton | 1 | 2007 | 1167 | 0.050 |
Why?
|
Photons | 1 | 2006 | 580 | 0.050 |
Why?
|
Palliative Care | 1 | 2018 | 3606 | 0.050 |
Why?
|
Vitrectomy | 1 | 2005 | 388 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2014 | 3613 | 0.050 |
Why?
|
Piperidines | 1 | 2010 | 1649 | 0.050 |
Why?
|
Cohort Studies | 3 | 2014 | 41247 | 0.050 |
Why?
|
Weight Loss | 1 | 2013 | 2673 | 0.050 |
Why?
|
Gene Silencing | 1 | 2007 | 1512 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12152 | 0.050 |
Why?
|
Eye Diseases | 1 | 2006 | 651 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2006 | 1265 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2012 | 8953 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 3478 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2012 | 4409 | 0.040 |
Why?
|
Drug Combinations | 1 | 2004 | 2023 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 4918 | 0.040 |
Why?
|
Normal Distribution | 1 | 2019 | 272 | 0.040 |
Why?
|
Sex Factors | 1 | 2012 | 10518 | 0.040 |
Why?
|
Functional Laterality | 1 | 2004 | 2253 | 0.040 |
Why?
|
Brain | 1 | 2004 | 26863 | 0.040 |
Why?
|
Neurofibromatosis 2 | 2 | 2012 | 385 | 0.040 |
Why?
|
Diabetic Retinopathy | 1 | 2005 | 1268 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2005 | 2142 | 0.030 |
Why?
|
Amygdala | 1 | 2023 | 1350 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2003 | 1376 | 0.030 |
Why?
|
Image Enhancement | 1 | 2006 | 2878 | 0.030 |
Why?
|
Body Mass Index | 1 | 2013 | 12874 | 0.030 |
Why?
|
Stroke | 1 | 2017 | 9935 | 0.030 |
Why?
|
DNA, Viral | 1 | 2022 | 2195 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2012 | 7851 | 0.030 |
Why?
|
Adenocarcinoma | 2 | 2009 | 6311 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 12964 | 0.030 |
Why?
|
Mice, Nude | 2 | 2012 | 3605 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6380 | 0.030 |
Why?
|
Probability | 1 | 2019 | 2475 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2023 | 2630 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9194 | 0.030 |
Why?
|
Recovery of Function | 1 | 2003 | 2979 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 11653 | 0.030 |
Why?
|
Down-Regulation | 2 | 2012 | 2920 | 0.030 |
Why?
|
Eye Burns | 1 | 2013 | 65 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2014 | 2448 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2010 | 800 | 0.020 |
Why?
|
Thrombospondins | 1 | 2012 | 193 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3468 | 0.020 |
Why?
|
Lasers, Solid-State | 1 | 2013 | 175 | 0.020 |
Why?
|
Permeability | 1 | 2012 | 719 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 894 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2010 | 384 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2005 | 15264 | 0.020 |
Why?
|
Transcription Factors | 1 | 2007 | 12106 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2012 | 2015 | 0.020 |
Why?
|
Cyclin D | 1 | 2007 | 72 | 0.020 |
Why?
|
Signal Transduction | 3 | 2019 | 23362 | 0.020 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2008 | 58 | 0.020 |
Why?
|
Disease Progression | 1 | 2004 | 13479 | 0.020 |
Why?
|
Cell Compartmentation | 1 | 2007 | 385 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6436 | 0.020 |
Why?
|
Prospective Studies | 1 | 2011 | 54204 | 0.020 |
Why?
|
Mice | 5 | 2013 | 81138 | 0.020 |
Why?
|
Blood Vessels | 1 | 2012 | 1112 | 0.020 |
Why?
|
Solubility | 1 | 2007 | 1087 | 0.020 |
Why?
|
Mutant Proteins | 1 | 2007 | 492 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11058 | 0.020 |
Why?
|
Cyclins | 1 | 2007 | 593 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2013 | 10440 | 0.010 |
Why?
|
Cell Cycle | 1 | 2013 | 2939 | 0.010 |
Why?
|
Cell Polarity | 1 | 2007 | 638 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2014 | 2866 | 0.010 |
Why?
|
Cell Line, Tumor | 2 | 2012 | 16871 | 0.010 |
Why?
|
Decision Making | 1 | 2018 | 3920 | 0.010 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 620 | 0.010 |
Why?
|
Endocytosis | 1 | 2007 | 960 | 0.010 |
Why?
|
Radiotherapy, Conformal | 1 | 2006 | 549 | 0.010 |
Why?
|
Cell Survival | 1 | 2013 | 5796 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2013 | 21981 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2007 | 3087 | 0.010 |
Why?
|
Cytoskeletal Proteins | 1 | 2007 | 1344 | 0.010 |
Why?
|
Protein Transport | 1 | 2007 | 1966 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 8000 | 0.010 |
Why?
|
Animals | 5 | 2013 | 167838 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2013 | 18110 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2007 | 3094 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8788 | 0.010 |
Why?
|
Protein Kinases | 1 | 2007 | 1612 | 0.010 |
Why?
|
Sirolimus | 1 | 2007 | 1548 | 0.010 |
Why?
|
Actins | 1 | 2007 | 2048 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12940 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2007 | 2061 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13946 | 0.010 |
Why?
|
Cell Membrane | 1 | 2007 | 3683 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6772 | 0.010 |
Why?
|
Fibroblasts | 1 | 2007 | 4084 | 0.010 |
Why?
|
Apoptosis | 1 | 2013 | 9492 | 0.010 |
Why?
|
Quality of Life | 1 | 2018 | 13284 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 24049 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 9374 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 8491 | 0.010 |
Why?
|
Protein Binding | 1 | 2007 | 9334 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2013 | 11476 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2007 | 9528 | 0.010 |
Why?
|
Cell Line | 1 | 2007 | 15636 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2007 | 5635 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2003 | 3449 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 11908 | 0.010 |
Why?
|
Mutation | 1 | 2014 | 29877 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2010 | 20461 | 0.000 |
Why?
|